Objective:

To systematically evaluate the predictive value of platelet parameters (PLT, PDW, MPV, PCT) before initial 131I therapy in patients with differentiated thyroid cancer.

Approach:

Key Findings:

• MPV was independently and negatively associated with non-ER (OR = 0.40, 95% CI 0.28–0.58).
• Age and ps-Tg influenced the association between MPV and non-ER (P = 0.042 and P = 0.031).
• MPV had a moderate predictive value for non-ER (AUC = 0.664).
• The optimal cutoff value for MPV was determined to be 9.95 fL, with a sensitivity of 0.595 and a specificity of 0.657.

Interpretation:

MPV demonstrated moderate predictive value in forecasting the response of DTC patients to initial 131I therapy.

Limitations:

• The study is retrospective, which may introduce bias.
• MPV alone is insufficient for clinical decision-making.

Conclusion:

MPV may help identify patients with poor treatment response at an early stage.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.